College of Pharmacy, Gansu University of Chinese Medicine, Lanzhou, PR China.
Key Laboratory of Standard and Quality of Chinese Medicine Research of Gansu, Engineering Research Center of Chinese Medicine Pharmaceutical Process of Gansu, Gansu University of Chinese Medicine, Lanzhou, PR China.
Pharm Biol. 2022 Dec;60(1):1237-1254. doi: 10.1080/13880209.2022.2086990.
Hedysari Radix Praeparata Cum Melle (HRPCM) and Astragali Radix Praeparata Cum Melle (ARPCM) are used interchangeably in clinics to treat spleen-qi deficiency (SQD) symptom mainly including gastrointestinal dysfunction and decreased immunity, which has unknown differences in efficacy.
To investigate the differences between HRPCM and ARPCM on intervening gastrointestinal- and immune-function with SQD syndrome.
After the SQD model was established, the Sprague-Dawley (SD) rats were randomly divided into nine groups ( = 10): normal; model; Bu-Zhong-Yi-Qi Pills; 18.9, 12.6 and 6.3 g/kg dose groups of HRPCM and ARPCM. Gastrointestinal function including d-xylose, gastrin, amylase vasoactive intestinal peptide, motilin, pepsin, H/K-ATPase, Na/K-ATPase, sodium-glucose cotransporter 1 (SGLT1), glucose transporter 2 (GLUT2) and immune function including spleen and thymus index, blood routine, interleukin (IL)-2, IL-6, interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α), immunoglobulin (Ig) M, IgA, IgG and delayed-type hypersensitivity (DTH) were detected. Finally, the efficacy differences were analysed comprehensively by the fuzzy matter-element method.
In regulating immune, the doses differences in efficacy between HRPCM and ARPCM showed in the high-dose (18.9 g/kg), but there were no differences in the middle- and low- dose (12.6 and 6.37 g/kg); the efficacy differences were primarily reflected in levels of IL-6, IFN-γ, TNF-α and IgM in serum, and the mRNA expression of IL-6 and IFN-γ in the spleen. In regulating gastrointestinal, the efficacy differences were primarily reflected in the levels of D-xylose, MTL, and GAS in serum, and the mRNA and protein expression of SGLT1 and GLUT2 in jejunum and ileum.
HRPCM is more effective than ARPCM on regulating gastrointestinal function and immune function with SQD syndrome. Therefore, we propose that HRPCM should be mainly used to treat SQD syndrome in the future.
炙甘草与蜜制黄芪在临床上常可互换使用，用于治疗主要表现为胃肠功能紊乱和免疫力下降的脾气虚证，但其疗效尚不清楚。
探讨炙甘草与蜜制黄芪干预脾气虚证胃肠-免疫功能的差异。
脾气虚证模型建立后，将 SD 大鼠随机分为 9 组（每组 10 只）：正常组；模型组；补中益气丸组；炙甘草与蜜制黄芪高、中、低剂量组（18.9、12.6 和 6.3 g/kg）。检测胃肠功能[包括血清 D-木糖、胃泌素、淀粉酶、血管活性肠肽、胃动素、胃蛋白酶、H+/K+-ATP 酶、Na+/K+-ATP 酶、钠-葡萄糖协同转运蛋白 1（SGLT1）、葡萄糖转运蛋白 2（GLUT2）]和免疫功能[包括脾、胸腺指数、血常规、白细胞介素（IL）-2、IL-6、干扰素-γ（IFN-γ）、肿瘤坏死因子-α（TNF-α）、免疫球蛋白（Ig）M、IgA、IgG 和迟发型超敏反应（DTH）]。最后，采用模糊物元法综合分析疗效差异。
在调节免疫方面，炙甘草与蜜制黄芪高、中、低剂量组（18.9、12.6 和 6.3 g/kg）疗效差异主要体现在血清中 IL-6、IFN-γ、TNF-α和 IgM 水平以及脾中 IL-6 和 IFN-γ mRNA 表达上；在调节胃肠功能方面，疗效差异主要体现在血清中 D-木糖、胃动素和胃泌素水平以及空肠和回肠中 SGLT1 和 GLUT2 mRNA 和蛋白表达上。
炙甘草在调节脾气虚证胃肠功能和免疫功能方面的作用优于蜜制黄芪。因此，我们建议在未来的临床应用中，炙甘草应主要用于脾气虚证的治疗。
